A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease

Trial Profile

A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Cramp
  • Focus Therapeutic Use
  • Acronyms COMMEND
  • Sponsors Flex Pharma
  • Most Recent Events

    • 02 Aug 2017 According to a Flex Pharma media release, company expects to report topline results from this study in the middle of 2018.
    • 01 Aug 2017 Status changed from not yet recruiting to recruiting according to a Flex Pharma media release.
    • 31 Jul 2017 According to a Flex Pharma media release, company is on track to initiate the trial this quarter and data readouts expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top